The therapeutic landscape of Hodgkin lymphoma has improved considerably over the past 50 years, with patient outcomes improving due to accurate diagnoses. Here, Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital, Paris, France, raises the issue that not all patients respond in the same way to therapy. Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Prof. Mohty discusses the factors that may introduce complications in therapy response, and how novel therapies may hold the key in delivering tailored care to patients.
Novel therapies in minimizing transplant complications
